Key result
Tocilizumab treatment in patients with active rheumatoid arthritis significantly reduced the corrected QT interval from a baseline of 452.3 ms to 428.1 ms at 6 months.
Why the study?
Does tocilizumab reduce the corrected QT (QTc) interval in patients with active rheumatoid arthritis?
Cohort (n=17)
No
Does tocilizumab reduce the corrected QT (QTc) interval in patients with active rheumatoid arthritis?
Mean Difference: -24.2
Absolute Event Rate: 428.1% vs 452.3%
Tocilizumab significantly reduces the QTc interval in patients with active rheumatoid arthritis, suggesting that controlling systemic inflammation may have antiarrhythmic potential.
Authors
No takes yet. Share an insight, caveat, or question.
May prompt QTc screening in RA to flag SCD risk; leaves open causal role of inflammation and therapeutic implications.
Lazzerini et al. (2014) conducted a cohort in Rheumatoid arthritis (n=17). Tocilizumab vs. Baseline (pre-treatment) was evaluated on Corrected QT interval (QTc) (Mean reduction of 24.2 ms). Tocilizumab treatment in patients with active rheumatoid arthritis significantly reduced the corrected QT interval from a baseline of 452.3 ms to 428.1 ms at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: